Article

Digestive Diseases and Sciences

, Volume 44, Issue 4, pp 845-851

First online:

Effect of Icatibant, a Bradykinin B2 Receptor Antagonist, on the Development of Experimental Ulcerative Colitis in Mice

  • Yoshinori Arai
  • , Hitoshi Takanashi
  • , Hiroshi Kitagawa
  • , Klaus J. Wirth
  • , Isao Okayasu

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Dextran sulfate sodium-induced colitis in micehas been recognized as a model for human ulcerativecolitis. Using this model, we carried out a study on thepreventive effect of Icatibant, a bradykinin B receptor antagonist previously called HOE 140,on the development of colitis. Subcutaneousadministration of Icatibant (0.3 or 1.5 mg/kg)significantly suppressed shortening of the largeintestine and worsening of the general health. Oraladministration of Icatibant (50 mg/kg) significantlysuppressed shortening of the large intestine, the onsetof diarrhea, and worsening of the general health. Inaddition, the oral treatment significantly inhibited thedevelopment of colitis that was observedhistopathologically. These results indicate a role of BKin the development of dextran sulfate sodiuminducedcolitis in mice, and suggest that BK could be importantin human ulcerative colitis.

ULCERATIVE COLITIS DEXTRAN SULFATE SODIUM ICATIBANT BRADYKININ